Cargando…
Addition of Aliskiren to Angiotensin Receptor Blocker Improves Ambulatory Blood Pressure Profile and Cardiorenal Function Better than Addition of Benazepril in Chronic Kidney Disease
An altered ambulatory blood pressure (BP) and heart rate (HR) profile is related to chronic kidney disease (CKD) and cardiorenal syndrome. In this study, we examined the effects of aliskiren, when added to angiotensin II type 1 receptor blockers, on ambulatory BP and cardiorenal function in CKD. Thi...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759864/ https://www.ncbi.nlm.nih.gov/pubmed/23887656 http://dx.doi.org/10.3390/ijms140815361 |
_version_ | 1782282697618489344 |
---|---|
author | Ohsawa, Masato Tamura, Kouichi Kanaoka, Tomohiko Wakui, Hiromichi Maeda, Akinobu Dejima, Toru Azushima, Kengo Uneda, Kazushi Kobayashi, Ryu Tsurumi-Ikeya, Yuko Toya, Yoshiyuki Fujikawa, Tetsuya Umemura, Satoshi |
author_facet | Ohsawa, Masato Tamura, Kouichi Kanaoka, Tomohiko Wakui, Hiromichi Maeda, Akinobu Dejima, Toru Azushima, Kengo Uneda, Kazushi Kobayashi, Ryu Tsurumi-Ikeya, Yuko Toya, Yoshiyuki Fujikawa, Tetsuya Umemura, Satoshi |
author_sort | Ohsawa, Masato |
collection | PubMed |
description | An altered ambulatory blood pressure (BP) and heart rate (HR) profile is related to chronic kidney disease (CKD) and cardiorenal syndrome. In this study, we examined the effects of aliskiren, when added to angiotensin II type 1 receptor blockers, on ambulatory BP and cardiorenal function in CKD. Thirty-six hypertensive CKD patients were randomly assigned to the aliskiren add-on group (n = 18) or the benazepril add-on group (n = 18). Ambulatory BP and cardiorenal function parameters were measured at baseline and 24 weeks after treatment. Compared with the benazepril group, nighttime systolic BP variability in the aliskiren group was lower after treatment. Albuminuria was decreased in the aliskiren group, but not in the benazepril group. In addition, left ventricular mass index (LVMI) was significantly lower in the aliskiren group than in the benazepril group after treatment. In the aliskiren group, multivariate linear regression analysis showed an association between changes in albuminuria and changes in nighttime systolic BP. Furthermore, there were associations between changes in LVMI and changes in daytime HR variability, as well as between changes in LVMI and changes in plasma aldosterone concentration. These results suggest that aliskiren add-on therapy may be beneficial for suppression of renal deterioration and pathological cardiac remodeling through an improvement that is effected in ambulatory BP and HR profiles. |
format | Online Article Text |
id | pubmed-3759864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-37598642013-09-03 Addition of Aliskiren to Angiotensin Receptor Blocker Improves Ambulatory Blood Pressure Profile and Cardiorenal Function Better than Addition of Benazepril in Chronic Kidney Disease Ohsawa, Masato Tamura, Kouichi Kanaoka, Tomohiko Wakui, Hiromichi Maeda, Akinobu Dejima, Toru Azushima, Kengo Uneda, Kazushi Kobayashi, Ryu Tsurumi-Ikeya, Yuko Toya, Yoshiyuki Fujikawa, Tetsuya Umemura, Satoshi Int J Mol Sci Article An altered ambulatory blood pressure (BP) and heart rate (HR) profile is related to chronic kidney disease (CKD) and cardiorenal syndrome. In this study, we examined the effects of aliskiren, when added to angiotensin II type 1 receptor blockers, on ambulatory BP and cardiorenal function in CKD. Thirty-six hypertensive CKD patients were randomly assigned to the aliskiren add-on group (n = 18) or the benazepril add-on group (n = 18). Ambulatory BP and cardiorenal function parameters were measured at baseline and 24 weeks after treatment. Compared with the benazepril group, nighttime systolic BP variability in the aliskiren group was lower after treatment. Albuminuria was decreased in the aliskiren group, but not in the benazepril group. In addition, left ventricular mass index (LVMI) was significantly lower in the aliskiren group than in the benazepril group after treatment. In the aliskiren group, multivariate linear regression analysis showed an association between changes in albuminuria and changes in nighttime systolic BP. Furthermore, there were associations between changes in LVMI and changes in daytime HR variability, as well as between changes in LVMI and changes in plasma aldosterone concentration. These results suggest that aliskiren add-on therapy may be beneficial for suppression of renal deterioration and pathological cardiac remodeling through an improvement that is effected in ambulatory BP and HR profiles. Molecular Diversity Preservation International (MDPI) 2013-07-24 /pmc/articles/PMC3759864/ /pubmed/23887656 http://dx.doi.org/10.3390/ijms140815361 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland http://creativecommons.org/licenses/by/3.0 This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Ohsawa, Masato Tamura, Kouichi Kanaoka, Tomohiko Wakui, Hiromichi Maeda, Akinobu Dejima, Toru Azushima, Kengo Uneda, Kazushi Kobayashi, Ryu Tsurumi-Ikeya, Yuko Toya, Yoshiyuki Fujikawa, Tetsuya Umemura, Satoshi Addition of Aliskiren to Angiotensin Receptor Blocker Improves Ambulatory Blood Pressure Profile and Cardiorenal Function Better than Addition of Benazepril in Chronic Kidney Disease |
title | Addition of Aliskiren to Angiotensin Receptor Blocker Improves Ambulatory Blood Pressure Profile and Cardiorenal Function Better than Addition of Benazepril in Chronic Kidney Disease |
title_full | Addition of Aliskiren to Angiotensin Receptor Blocker Improves Ambulatory Blood Pressure Profile and Cardiorenal Function Better than Addition of Benazepril in Chronic Kidney Disease |
title_fullStr | Addition of Aliskiren to Angiotensin Receptor Blocker Improves Ambulatory Blood Pressure Profile and Cardiorenal Function Better than Addition of Benazepril in Chronic Kidney Disease |
title_full_unstemmed | Addition of Aliskiren to Angiotensin Receptor Blocker Improves Ambulatory Blood Pressure Profile and Cardiorenal Function Better than Addition of Benazepril in Chronic Kidney Disease |
title_short | Addition of Aliskiren to Angiotensin Receptor Blocker Improves Ambulatory Blood Pressure Profile and Cardiorenal Function Better than Addition of Benazepril in Chronic Kidney Disease |
title_sort | addition of aliskiren to angiotensin receptor blocker improves ambulatory blood pressure profile and cardiorenal function better than addition of benazepril in chronic kidney disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759864/ https://www.ncbi.nlm.nih.gov/pubmed/23887656 http://dx.doi.org/10.3390/ijms140815361 |
work_keys_str_mv | AT ohsawamasato additionofaliskirentoangiotensinreceptorblockerimprovesambulatorybloodpressureprofileandcardiorenalfunctionbetterthanadditionofbenazeprilinchronickidneydisease AT tamurakouichi additionofaliskirentoangiotensinreceptorblockerimprovesambulatorybloodpressureprofileandcardiorenalfunctionbetterthanadditionofbenazeprilinchronickidneydisease AT kanaokatomohiko additionofaliskirentoangiotensinreceptorblockerimprovesambulatorybloodpressureprofileandcardiorenalfunctionbetterthanadditionofbenazeprilinchronickidneydisease AT wakuihiromichi additionofaliskirentoangiotensinreceptorblockerimprovesambulatorybloodpressureprofileandcardiorenalfunctionbetterthanadditionofbenazeprilinchronickidneydisease AT maedaakinobu additionofaliskirentoangiotensinreceptorblockerimprovesambulatorybloodpressureprofileandcardiorenalfunctionbetterthanadditionofbenazeprilinchronickidneydisease AT dejimatoru additionofaliskirentoangiotensinreceptorblockerimprovesambulatorybloodpressureprofileandcardiorenalfunctionbetterthanadditionofbenazeprilinchronickidneydisease AT azushimakengo additionofaliskirentoangiotensinreceptorblockerimprovesambulatorybloodpressureprofileandcardiorenalfunctionbetterthanadditionofbenazeprilinchronickidneydisease AT unedakazushi additionofaliskirentoangiotensinreceptorblockerimprovesambulatorybloodpressureprofileandcardiorenalfunctionbetterthanadditionofbenazeprilinchronickidneydisease AT kobayashiryu additionofaliskirentoangiotensinreceptorblockerimprovesambulatorybloodpressureprofileandcardiorenalfunctionbetterthanadditionofbenazeprilinchronickidneydisease AT tsurumiikeyayuko additionofaliskirentoangiotensinreceptorblockerimprovesambulatorybloodpressureprofileandcardiorenalfunctionbetterthanadditionofbenazeprilinchronickidneydisease AT toyayoshiyuki additionofaliskirentoangiotensinreceptorblockerimprovesambulatorybloodpressureprofileandcardiorenalfunctionbetterthanadditionofbenazeprilinchronickidneydisease AT fujikawatetsuya additionofaliskirentoangiotensinreceptorblockerimprovesambulatorybloodpressureprofileandcardiorenalfunctionbetterthanadditionofbenazeprilinchronickidneydisease AT umemurasatoshi additionofaliskirentoangiotensinreceptorblockerimprovesambulatorybloodpressureprofileandcardiorenalfunctionbetterthanadditionofbenazeprilinchronickidneydisease |